Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have recently been diagnosed with kidney cancer (renal cell carcinoma) for the first time
- People who have not yet received any treatment for their cancer
- People who are willing to have surgery to remove the affected kidney or tumour
- People who have signed a written consent form agreeing to take part
- People whose general health and ability to carry out daily activities meets a specific standard (rated 0 or 1 on a medical scale, meaning fully active or able to carry out light work)
- People who are able and willing to attend follow-up appointments and complete the required procedures during the trial
Who may not be able to join:
- People who have had, or currently have, another type of cancer
- People who have previously received any cancer treatment
- People who are known or suspected to have an active autoimmune disease (a condition where the immune system attacks the body)
- People who are unable to give informed consent due to a medical or mental health condition
- People who have heart-related symptoms or heart conditions that are not well managed
- People who the trial doctors consider to be unsuitable for the study for any reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 15720625951
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma.; To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging.; The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles.; A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.